The product license holder of rupatadine (Rupafin®) has written to healthcare professionals advising that with effect from the 31st March 2015 this medicine will be effectively discontinued in the UK.
An agreement between the license holder and a UK based distributor has come to an end and a new distributor is not being sought. It is estimated that supplies would be exhausted by the end of March 2015. As such alternative treatment options will need to be considered.
Action: Clinicians should be aware of the product being discontinued. It may be prudent to run clinical system searches to identify any patients who are currently prescribed this product to allow an alternative to be arranged.
|« Follow using Twitter||BNF 69 »|